clinical trial · NCT07541287
A Phase 2 Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Jade Biosciences, Inc.·phase2·not yet recruiting·n = 30
IgA NephropathyJADE101
brief summary
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.
started
May 1, 2026
primary completion
Jan 1, 2029
completion
Apr 1, 2029
last updated
Apr 21, 2026
official title
A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants With Immunoglobulin A Nephropathy (JUNIPER)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol